Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis

Andrew Blauvelt(Veterans Health Administration), Richard G. Langley(Dalhousie University)

JAMA Dermatology

April 8, 2020

10.1001/jamadermatol.2020.0723

Cited by 209

Related Papers

Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis

|New England Journal of Medicine|2016|2k

The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis

|Clinical Reviews in Allergy & Immunology|2018|738

Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*

|British Journal of Dermatology|2020|590

Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial

|The Lancet|2015|566

Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials

|The Lancet|2021|538